<unk> , sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.<unk>  was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. It is available as a generic medication.
Cabazitaxel
Docetaxel
Paclitaxel
Doxorubicin
Ifosfamide
Lipoplatin
Bendamustine
Normustine